

Jun 27, 2024

Mutant generation in Streptococcus mitis strain B6

DOI

<https://dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1>

Samantha King¹

¹Nationwide Children's Hospital



Samantha King

Nationwide Children's Hospital

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1>

Protocol Citation: Samantha King 2024. Mutant generation in Streptococcus mitis strain B6. protocols.io
<https://dx.doi.org/10.17504/protocols.io.261ge5ezyg47/v1>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: June 26, 2024

Last Modified: June 27, 2024

Protocol Integer ID: 102478

Keywords: Transformation, mutagenesis, *Streptococcus mitis* B6, mutant generation in streptococcus, insertion deletion mutants in streptococcus, mitis strain b6 this protocol, mitis strain b6, insertion deletion mutant, streptococcus, mutant generation

Funders Acknowledgements:

American Heart Association

Grant ID: 19TPA34760750

Abstract

This protocol is the methodology that we have successfully employed to generate and confirm insertion deletion mutants in *Streptococcus mitis* strain B6. Attached to the protocol is a file that includes primers for the MonX mutation

Attachments



B6 mutagenesis of Mo...

14KB

Materials

Table 1: Primers Used in This Study

	A	B	C	D
	Target	Name	Sequence 5' to 3'	Location (accession no.)
	Spec	S1	CGATTTTCGTTTCGTGAATAC	5418–5399 (KM009065)
		S2	TATGCAAGGGTTTATTGTTTTC	4265–4286 (KM009065)
	pJet	P1	CGACTCACTATAGGGAGAGCGG C	310–332 (EF694056.1)
		P2	AAGAACATCGATTTTCCATGGCA G	405–428 (EF694056.1)

Safety warnings

 Appropriate biosafety procedures need to be followed

***Streptococcus mitis* B6 mutagenesis protocol**

1

Creation of a plasmid construct

- 1.1 The regions upstream and downstream of the region to be deleted were amplified using primers 1 and 2, and 3 and 4, respectively. These primers were designed to contain appropriate overhangs to allow In-fusion with pJET 1.2/blunt and the antibiotic resistance cassette.
- 1.2 The spectinomycin resistance cassette (*aad9*) was amplified using primers S1 and S2
- 1.3 PCR products were then purified with a Qiagen PCR Purification Kit
- 1.4 The three fragments for each mutant construct were cloned into pJET 1.2/Blunt (Thermo Fisher Scientific) using In-Fusion Snap Assembly (Takara) and transformed into *Escherichia coli* stellar competent cells.
- 1.5 Transformants were selected on LB agar plates supplemented with ampicillin (100 µg/ml) and incubated at 37°C overnight
- 1.6 The resulting colonies were confirmed as ampicillin resistant by streaking on a new LB agar plate supplemented with ampicillin (100 µg/ml).
- 1.7 Transformants were screened by colony PCR using pJET 1.2/blunt Fwd and Rev primers.
- 1.8 For transformants giving an appropriate PCR product, a 5 mL LB culture supplemented with ampicillin (100 µg/ml) was grown overnight at 37 °C with shaking at 200 rpm.
- 1.9 The plasmid was then purified using Qiagen Miniprep Kit and confirmed by sequencing

2 Transformation of *S. mitis* B6

- 2.1 Strains were growth at 37°C in C+Y pH8 [1] – starting at a low inoculum i.e. from a plate or diluting from a culture 1:100 (starting optical density at 600nm [OD₆₀₀] = 0.03 to 0.05).
- 2.2 When the culture was close to OD₆₀₀ =0.1, 950 µl of C+Y pH 8.0 medium was added to a 1.5 ml tube with 10 µl of 100 mM CaCl₂, 2 µl of competence stimulating peptide (CSP) (EMRKPDGALFNLFRRR - 1 mg/ml), and 150 ng of DNA. A no DNA control tube is included to account for potential contamination. These tubes were prewarmed in a waterbath to 37°C.
- 2.3 When the culture reached an OD₆₀₀ of 0.10 to 0.12, 50 µl of culture was added to the prewarmed tubes.
- 2.4 Tubes were incubated in a waterbath at 37 °C for 2 hr.
- 2.5 Reactions were pelleted by centrifugation and resuspended in approximately 100 µl of media. This was plated on selective Tryptic Soy Agar (TSA) plates spread with 5000 U catalase (Worthington Biochemical Corporation).
- 2.6 Plates were incubated at 37°C in 5% CO₂ overnight and then patched onto selective plates.

3 **Confirmation of putative transformants**

- 3.1 Putative transformants were grown in tryptic soy broth and DNA prepared as previously described [2].
- 3.2 The mutations were confirmed by PCR and sequencing (using primers S1 and S2) or genome sequencing.



Protocol references

1. LACKS S, HOTCHKISS RD. A study of the genetic material determining an enzyme in *Pneumococcus*. *Biochim Biophys Acta*. 1960;39:508-18. doi: 10.1016/0006-3002(60)90205-5. PubMed PMID: 14413322.
2. Gaytán MO, Singh AK, Woodiga SA, Patel SA, An SS, Vera-Ponce de León A, et al. A novel sialic acid-binding adhesin present in multiple species contributes to the pathogenesis of Infective endocarditis. *PLoS Pathog*. 2021;17(1):e1009222. Epub 20210119. doi: 10.1371/journal.ppat.1009222. PubMed PMID: 33465168; PubMed Central PMCID: PMC7846122.